3Kaushansky K,Lok S,Holly RD,et al.Promotion of megaka-ryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin[J].Nature,1994,369:568～571.
4Borge OJ,Ramsfjell V,Veiby OP,et al.Thrombopoietin,but not erythropoietin promotes viability and inhibits apoptosis of multipotent murinehematopoietic progenitor cells in vitro[J].Blood,1996,88:2859～2870.
5David J,Kuter and C,Glenn Begley.Recombinant human thrombopoietin:basic biology and evalution of clinical studies[J].Blood,2002,100(10):3457～3469.
6Archimbaud E,Ottmann OG,Yin JA,et al.A randomized,double-blind,placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor(PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia[J].Blood,1999,94:3694～3701.
7Nash R,Kurzrock R,Dipersio J,et al.Safety and activity of recombinant human thrombopoietin (rhTPO) in patients(pts) with delayed platelet recovery(DPR)[J],Blood,1997,90:262a.
8Von dem BA,Folman C,linthorst G,et al.The potential role of thrombopoietin in idiopathic thrombocytopenic purpura[J].Blood Rev,2002,16(1):57～59.
9Dan K,Nomura S,Hotta T,et al.Biological effect of pegylated recombinant human megakaryocyte growth and development factor(PEG-rHuMGDF) in patients with idiopathic thrombocytopenic purpura[J].Blood,2001,98:299.
10Berchtold P,McMillan R.Therapy of chronic idiopathic thrombocy-topenic Purpura in adults.Blood,1989,74(7):2309-2317.
6Spencer FA.Heparin-induced thrombocytopenia:patient profiles and clinical manifestations[J].J Thrombosis Thrombolytic,2000,10:S21.
7Okamoto H,Yamamura M,Morita Y,et al.The synovial expression and serum levels of inter leukin-6,interleukin-11,leukemia inhibitory factor,and oncostatin M in rheumatoid arthritis[J].Arthritis Rheum,1997,40(6):1096-1105.
8Nicola MD,Maurizia BD.EDTA-dependent pseudothrom bocytopenia association with antiplateletand antiphospholipid antibodies[J].Am J Clin Pathol,1995,103:103.
